X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (40327) 40327
Book Review (7966) 7966
Publication (4152) 4152
Newsletter (3583) 3583
Newspaper Article (1427) 1427
Magazine Article (357) 357
Book Chapter (201) 201
Conference Proceeding (132) 132
Trade Publication Article (84) 84
Book / eBook (55) 55
Transcript (34) 34
Dissertation (18) 18
Data Set (10) 10
Reference (9) 9
Government Document (8) 8
Web Resource (6) 6
Streaming Video (4) 4
Report (3) 3
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (33771) 33771
humans (30509) 30509
antiviral agents (19972) 19972
female (15094) 15094
male (14746) 14746
antiviral agents - therapeutic use (14016) 14016
adult (10828) 10828
antiviral agents - administration & dosage (10544) 10544
middle aged (9466) 9466
animals (8753) 8753
health aspects (8028) 8028
drug therapy (7334) 7334
hiv (7122) 7122
infectious diseases (6624) 6624
treatment outcome (6408) 6408
pharmacology & pharmacy (6096) 6096
virology (5985) 5985
infection (5750) 5750
research (5617) 5617
drug therapy, combination (5420) 5420
dosage and administration (5389) 5389
antiviral agents - pharmacology (5147) 5147
care and treatment (4878) 4878
immunology (4863) 4863
hepatitis c, chronic - drug therapy (4711) 4711
hiv infections - drug therapy (4628) 4628
analysis (4542) 4542
viruses (4418) 4418
aged (4362) 4362
therapy (4250) 4250
hepatitis c (4242) 4242
gastroenterology & hepatology (4197) 4197
hiv infection (4088) 4088
virus diseases (4055) 4055
aids (3996) 3996
antiviral agents - adverse effects (3980) 3980
microbiology (3859) 3859
mice (3823) 3823
infections (3769) 3769
interferon (3585) 3585
human immunodeficiency virus--hiv (3527) 3527
risk factors (3516) 3516
hepatitis c virus (3511) 3511
abridged index medicus (3281) 3281
viral load (3138) 3138
hepatitis (3135) 3135
adolescent (3087) 3087
ribavirin (3019) 3019
prevention (2820) 2820
interferon-alpha - therapeutic use (2761) 2761
highly active antiretroviral therapy (2660) 2660
interferon-alpha - administration & dosage (2637) 2637
ribavirin - administration & dosage (2613) 2613
ribavirin - therapeutic use (2550) 2550
anti-hiv agents (2527) 2527
genotype (2493) 2493
antiretroviral therapy (2470) 2470
medical research (2459) 2459
hepacivirus - genetics (2423) 2423
time factors (2417) 2417
young adult (2409) 2409
medicine (2346) 2346
research article (2345) 2345
aids/hiv (2321) 2321
recombinant proteins (2304) 2304
influenza (2256) 2256
hepatitis b (2182) 2182
drugs (2180) 2180
retrospective studies (2139) 2139
hepatitis c - drug therapy (2128) 2128
child (2123) 2123
virus-infection (2087) 2087
antiretroviral drugs (2081) 2081
drug administration schedule (2026) 2026
medicine, general & internal (2003) 2003
transplantation (1966) 1966
virus replication - drug effects (1908) 1908
administration, oral (1907) 1907
hepatitis b, chronic - drug therapy (1899) 1899
medicine, experimental (1880) 1880
disease (1879) 1879
usage (1870) 1870
article (1854) 1854
mortality (1845) 1845
human-immunodeficiency-virus (1835) 1835
hiv patients (1821) 1821
liver (1817) 1817
anti-hiv agents - therapeutic use (1815) 1815
multidisciplinary sciences (1792) 1792
antiviral therapy (1791) 1791
in-vitro (1776) 1776
antiviral activity (1765) 1765
hepacivirus - drug effects (1763) 1763
patients (1754) 1754
dose-response relationship, drug (1736) 1736
medicine & public health (1731) 1731
replication (1728) 1728
clinical trials (1725) 1725
human immunodeficiency virus (1723) 1723
antiviral agents - pharmacokinetics (1721) 1721
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (43) 43
Online Resources - Online (6) 6
Collection Dvlpm't (Acquisitions) - Closed Orders (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
UofT at Mississauga - Stacks (2) 2
Credit Valley Hospital - Stacks (1) 1
Scarborough Hospital - Hospital Department (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (43781) 43781
French (322) 322
Japanese (317) 317
Russian (316) 316
German (287) 287
Chinese (250) 250
Spanish (245) 245
Polish (85) 85
Korean (53) 53
Hungarian (46) 46
Italian (40) 40
Danish (33) 33
Dutch (29) 29
Swedish (27) 27
Czech (23) 23
Portuguese (18) 18
Croatian (17) 17
Norwegian (14) 14
Romanian (10) 10
Ukrainian (10) 10
Serbian (9) 9
Hebrew (7) 7
Turkish (5) 5
Arabic (4) 4
Bulgarian (4) 4
Finnish (4) 4
Slovak (3) 3
Bosnian (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Infectious Diseases, ISSN 1058-4838, 6/2011, Volume 52, Issue 11, pp. 1374 - 1383
Background. The optimal time to initiate antiretroviral therapy (ART) in human immunodeficiency virus (HIV)—associated tuberculous meningitis is unknown.... 
Statistical median | HIV/AIDS | Antiretrovirals | Art therapy | Meningeal tuberculosis | HIV | Mortality | Random allocation | AIDS | Arts | HIV 1 | MORTALITY | SURVIVAL | THAILAND | INFECTIOUS DISEASES | HIV-INFECTION | ERA | ADOLESCENTS | CLINICAL-TRIALS | ADULTS | RISK | MICROBIOLOGY | IMMUNOLOGY | Lamivudine - administration & dosage | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Time Factors | Adult | Anti-Inflammatory Agents - administration & dosage | Female | HIV Infections - mortality | Antiretroviral Therapy, Highly Active - methods | Tuberculosis, Meningeal - mortality | Placebos - administration & dosage | Dexamethasone - administration & dosage | Tuberculosis, Meningeal - drug therapy | Benzoxazines - administration & dosage | Double-Blind Method | Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage | Anti-HIV Agents - adverse effects | Treatment Outcome | Tuberculosis, Meningeal - complications | HIV Infections - complications | Antitubercular Agents - administration & dosage | HIV Infections - drug therapy | Antiviral agents | Care and treatment | Patient outcomes | Dosage and administration | Drug therapy | Health aspects | HIV infection | Comorbid patients | Tuberculous meningitis | Clinical trials | Antiretroviral drugs | Meningitis | Human immunodeficiency virus--HIV | Risk assessment | Medical treatment | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2429 - 2438
Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | PHARMACOKINETICS | SAFETY | NAIVE HIV-1-INFECTED PATIENTS | TREATMENT-EXPERIENCED PATIENTS | EFAVIRENZ | ADULTS | ANTIRETROVIRAL THERAPY | SINGLE-TABLET REGIMEN | PATIENTS 96-WEEK EFFICACY | COMBINATION | HIV-1 | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Atazanavir Sulfate | Adult | Female | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Antiretroviral drugs | Bone density | Pharmaceutical industry | Human immunodeficiency virus--HIV | Pneumonia | Laboratories | Ritonavir | Liver | Infections | Drug resistance | Hepatitis | Randomization | All terrain vehicles | Creatinine | Integrase | Data processing | Proteinase inhibitors | Behavior disorders | Ribonucleic acid--RNA | Patients | Cholesterol | Glomerular filtration rate | Inhibitors | Protease inhibitors | Interactive systems | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2011, Volume 365, Issue 16, pp. 1471 - 1481
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 07/2013, Volume 38, Issue 2, pp. 98 - 106
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2439 - 2448
Summary Background The integrase inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and... 
Internal Medicine | NON-INFERIORITY | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | RALTEGRAVIR | TREATMENT-EXPERIENCED PATIENTS | DISOPROXIL FUMARATE | ADULTS | ANTIRETROVIRAL THERAPY | SINGLE-TABLET REGIMEN | RILPIVIRINE | TREATMENT-NAIVE PATIENTS | Emtricitabine | HIV-1 | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Deoxycytidine - administration & dosage | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Adenine - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Organophosphonates - administration & dosage | Quinolones - administration & dosage | Adult | Female | HIV Infections - drug therapy | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Clinical trials | Antiretroviral drugs | Pharmaceutical industry | Human immunodeficiency virus--HIV | Creatinine | Integrase | Laboratories | Data processing | Infections | Nausea | Ribonucleic acid--RNA | Patients | Efavirenz | Dreams | Sleep disorders | Hepatitis | Dyspnea | Inhibitors | Protease inhibitors | Insomnia | Suicides & suicide attempts | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2017, Volume 66, Issue 6, pp. 1138 - 1148
Graphical abstract 
Gastroenterology and Hepatology | Antiviral agents | Ombitasvir | Ritonavir | Ledipasvir | Real-world | Genotype 1 | Paritaprevir | Sustained virologic response | Hepatitis C, Chronic | Sofosbuvir | Dasabuvir | Randomized controlled trials | PLUS RIBAVIRIN | VIRUS-INFECTION | CHRONIC HEPATITIS-C | SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | Chronic | HEPATOCELLULAR-CARCINOMA | TREATMENT-EXPERIENCED PATIENTS | Hepatitis C | GASTROENTEROLOGY & HEPATOLOGY | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepatitis C, Chronic - physiopathology | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Neoplasm Recurrence, Local - etiology | Liver Neoplasms - etiology | Young Adult | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Carcinoma, Hepatocellular - etiology | Retrospective Studies | Drug Therapy, Combination | Glomerular Filtration Rate | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Spain | Anilides - administration & dosage | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Sulfonamides - administration & dosage | Cohort Studies | Uracil - analogs & derivatives | Genetic aspects | Safety and security measures | Hepatitis C virus | Clinical trials | Chronic infection | Data processing | Hepatocellular carcinoma | Multivariate analysis | Patients | Clinical outcomes | Ribavirin | Genotype & phenotype | Cohort analysis | Fibrosis | Safety | Drug therapy | Antiviral drugs | Genotypes | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article